News - Bonvadis®

News & Insights

•2025-10-03•News
The medical device registration application of Bonvadis® for all indications of wounds has been accepted by COFEPRIS in Mexico.
The advanced wound care market in Mexico and Latin America is experiencing significant growth, driven by an increase in the number of injuries caused by chronic diseases, particularly diabetes. Mexico is the second largest healthcare market in Latin America, with a diabetes prevalence rate of 16.4%, and there is an urgent need for efficient chronic wound care.
Read More
•2025-10-03•News
The medical device registration application of Bonvadis® for all indications in wounds has been accepted by ThaiFDA.
According to the International Diabetes Federation (IDF), there are approximately 6.36 million people with diabetes in Thailand. However, due to the lack of effective and cost-effective drugs or medical devices for chronic wounds, the annual burden of wound care is currently estimated to exceed USD 700 million (Int Wound J. 2023 Nov 14;20(10): 3935–3938).
Read More
•2025-07-28•News
The medical device registration application of Bonvadis® for all indications in wounds has been accepted by Morocco AMMPS.
Oneness has received notification from the agent today that the medical device registration application of Bonvadis® for all indications has been accepted by AMMPS in Morocco.
Read More
•2025-06-10•News
Today, Bonvadis® is 510(k) cleared by the U.S. FDA for full-thickness chronic wounds, marking a significant milestone in international commercialization.
After a three-year, three-phase application process, our product has obtained 510(k) clearances in the U.S for various acute and chronic wound indications.
Read More
•2025-05-21•News
Bonvadis® topical cream received medical device marketing authorization approval for all indications in wounds for Australia.
Oneness has received notification from the agent today that the product topical cream received medical device marketing authorization approval for all indications in wounds under ARTG certificate number DV-2025-MC-09357-1 and with permission to be marketed in the Australia.
Read More
•2025-05-09•News
The medical device registration application of Bonvadis® for all indications in wounds has been accepted by India CDSCO.
According to Invest India, the country’s medical device market is valued at approximately USD 11 billion and is one of the fastest-growing among emerging markets. With a projected 15% CAGR — 2.5 times the global average — the market is expected to reach USD 50 billion by 2030.
Read More

Events

2025-09-12Italy, Pisa

Oneness Biotech to participate in the 16th International Diabetic Foot Course 2025

Oneness Biotech is excited to join the 16th International Diabetic Foot Course (Oct 1–4, 2025, Hotel San Ranieri, Pisa, Italy), a premier global platform where clinicians, researchers, and industry leaders come together with a shared mission: advancing DFU care and improving patient outcomes.

2025-09-02Las Vegas, USA

Expert Talks – Meet Dr. Chia-Ding Shih, DPM on September 5th 1:00 PM at SAWC Fall 2025

Meet Dr. Shih: Board-certified podiatric surgeon in chronic wounds of the foot and ankle. Published researcher in diabetic foot care and amputation prevention. Mentor and thought leader in podiatric medicine and limb preservation

2025-09-02Las Vegas, USA

Expert Talks – Meet Dr. Daniel L. Kapp, MD on September 4th 5:30 PM at SAWC Fall 2025

Meet Dr. Kapp: Experienced Board Certified Plastic Surgeon Nationally recognized expert in complex wound care management utilizing advanced biologics and cutting-edge technology Respected thought advisor to a number of pharmaceutical and medical device companies

2025-09-02Las Vegas, USA

Oneness Biotech to Exhibit at the Symposium on Advanced Wound Care (SAWC) Fall 2025

Oneness Biotech Co., Ltd. is proud to announce its participation in the Symposium on Advanced Wound Care (SAWC) Fall 2025, taking place in the United States. As one of the leading events in the field of wound care, SAWC Fall attracts thousands of clinicians, researchers, and industry professionals from around the world.

2025-05-04Grapevine, Texas, USA

Oneness Biotech Participated in SAWC | WHS Spring meeting on April 30-May 4, 2025

The Symposium on Advanced Wound Care (SAWC) Spring | Wound Healing Society (WHS) is the leading meeting dedicated to the management, treatment, and prevention of wounds. This year, the event was co-hosted with The Wound Care Collaborative Community (WCCC) Driving Innovation Summit to bring together the latest education on wound care prevention and management, scientific excellence, and the development of innovative wound-healing therapies to improve patient outcomes.

2025-03-31Barcelona, Spain

Oneness Biotech Participated in European Wound Management Association 2025 Annual Conference

The European Wound Management Association (EWMA) Annual Conference is one of the most prominent international events in the field of wound care, bringing together clinicians, researchers, and industry professionals to share the latest developments in wound management, clinical practices, and innovation.

2023-05-10The Hague, The Netherlands

Oneness Biotech to attend 9th International Symposium on the Diabetic Foot | World Forum

The Diabetic Foot Symposium, held once every four years, is the largest and most prestigious meeting worldwide devoted to lower extremity problems in diabetes. It has accomplished this unique position by bringing together delegates from many specialties and the leading experts in various fields, both from all over the world. Participating in this event will give you the unique opportunity to communicate with the experts in the field.

2023-04-26Maryland, USA

Oneness Biotech to attend SAWC Spring | WHS meeting in National Harbor

2023 SAWC Spring / WHS Meeting - Symposium On Advanced Wound Care / Wound Healing Society

News & Insights

The medical device registration application of Bonvadis® for all indications of wounds has been accepted by COFEPRIS in Mexico.

The medical device registration application of Bonvadis® for all indications in wounds has been accepted by ThaiFDA.

The medical device registration application of Bonvadis® for all indications in wounds has been accepted by Morocco AMMPS.

Today, Bonvadis® is 510(k) cleared by the U.S. FDA for full-thickness chronic wounds, marking a significant milestone in international commercialization.

Bonvadis® topical cream received medical device marketing authorization approval for all indications in wounds for Australia.

The medical device registration application of Bonvadis® for all indications in wounds has been accepted by India CDSCO.

Events

Oneness Biotech to participate in the 16th International Diabetic Foot Course 2025

Expert Talks – Meet Dr. Chia-Ding Shih, DPM on September 5th 1:00 PM at SAWC Fall 2025

Expert Talks – Meet Dr. Daniel L. Kapp, MD on September 4th 5:30 PM at SAWC Fall 2025

Oneness Biotech to Exhibit at the Symposium on Advanced Wound Care (SAWC) Fall 2025

Oneness Biotech Participated in SAWC | WHS Spring meeting on April 30-May 4, 2025

Oneness Biotech Participated in European Wound Management Association 2025 Annual Conference

Oneness Biotech to attend 9th International Symposium on the Diabetic Foot | World Forum

Oneness Biotech to attend SAWC Spring | WHS meeting in National Harbor

Media Gallery

Bonvadis Topical Cream (US Rx) Secondary Packaging

Bonvadis Topical Cream (US Rx) Primary Packaging

Bonvadis Topical Cream (US Rx) Primary and Secondary Packaging